Analytical Data
-
Gene name
CYP2A6
- Application
-
Alternative Names
CYP2A6；CYP2A3；Cytochrome P450 2A6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11509
-
Expression Region
29-494aa
-
AA Sequence
SKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR
-
Molecular Weight
53.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2A6 is a member of the cytochrome P450 enzyme family, playing a crucial role in the metabolism of various drugs and xenobiotics, as well as nicotine in the context of tobacco use. Due to its significant influence on pharmacokinetics and toxicity, polymorphisms in the CYP2A6 gene can lead to inter-individual variability in drug response and the risk of developing smoking-related diseases. Understanding the enzymatic mechanisms of CYP2A6 is essential for drug development, toxicology, and personalized medicine approaches. The study of recombinant CYP2A6 proteins enables researchers to investigate the enzyme’s kinetic properties, substrate specificity, and inhibition patterns in a controlled laboratory setting. By producing and characterizing these recombinant proteins, scientists can also examine the influence of genetic variations on enzyme activity, facilitating insights into patient-specific drug therapies. Advances in recombinant DNA technology have made it possible to generate these proteins efficiently, providing a valuable tool for drug metabolism research and contributing to the broader understanding of cytochrome P450 enzymes and their role in human health.
